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Abstract: Introduction: The quality of interventions in children is largely dependent on their control. Hence, this study
compared the sedative effects of subcutaneous (SC) and intravenous (IV) Midazolam in pediatric sedation in-
duction. Methods: This randomized clinical trial was conducted on children aged 1-6 years presenting to emer-
gency departments of Shahid Sadoughi and Shahid Rahnemoon Hospitals, Yazd, Iran. Participants were ran-
domly assigned to IV or SC midazolam using a jet injector and success rate, degree of sedation, and satisfaction
of parents and physician were compared between groups. Results: 60 cases with the mean age of 3.15±1.43
(1-6) years were randomly assigned to the SC (30 cases) or IV (30 cases) groups (56.7% female). SC and IV groups
were similar regarding the mean age (p = 0.165) and sex (p = 0.121). Depth of sedation (p=0.900), control of child
(p=0.711), in-charge physician’s satisfaction (p=0.467), successful sedation and need for rescue dose (p=0.519)
were not different between groups. IV midazolam group had a significantly shorter recovery time (about 10 min-
utes; p=0.040) and SC midazolam group had a significantly higher level of parent satisfaction (p=0.001). Conclu-
sion: The findings indicate no significant difference in depth of sedation, control of child, in-charge physician’s
satisfaction, successful sedation (reaching stage 1 of sedation or higher), and need for rescue dose of SC and IV
midazolam. Parents’ satisfaction was significantly greater with SC administration and IV injection had shorter
recovery time.
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1. Introduction
M
any patients present to the emergency department
(ED). Children are vulnerable to many diseases
and constitute a considerable number of traumatic
patients presenting to ED. The correct implementation of di-
agnostic procedures requires control and tranquility of chil-
dren as lack of children’s cooperation due to anxiety and dis-
comfort leads to lengthening of diagnostic procedures and
reduces their quality. So, the use of sedatives is mandatory
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in younger children to increase the quality of the provided
interventions and shorten the duration of these procedures.
The use of diagnostic procedures and minor surgical oper-
ations outside the operating room has increased over the
last decade. Yet, the administration of sedatives to children
is associated with risks like hypoventilation, apnea, airway
obstruction, laryngospasm, and impaired cardiopulmonary
functioning. Hence, the selection of appropriate drugs for
diagnostic and therapeutic interventions is as important as
the diplomacy and tactfulness of the in-charge physician in
reacting to drug complications (1-5). Midazolam is a short-
acting benzodiazepine with sedative, narcotic, anxiolytic, an-
ticonvulsive, and relaxing effects (1, 6, 7). Its acute complica-
tions include respiratory suppression and apnea which occur
rarely in cases of rapid injection of high doses of the drug. Ad-
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ditionally, Midazolam is a rapid-acting sedative with minimal
effect on blood oxygenation level and cerebral blood flow,
which renders it a suitable drug for cerebral imaging stud-
ies like MRI (6). Midazolam can be administered via intra-
venous (IV), subcutaneous (SC), muscular, intranasal, buc-
cal, and rectal routes. One modality of Midazolam adminis-
tration is the subcutaneous injection in which the drug effect
is initiated in 7 minutes reaching a peak during 23-49 min-
utes. The onset of IV Midazolam effect is 3-5 min, which is
finally eliminated by the liver (7, 8). Given that the subcu-
taneous injection with a jet injector is almost painless, and
also based on what has been said so far and considering the
lack of sufficient related studies in this field, especially on the
use of jet injector in ED (9-11), we embarked on comparing
the SC midazolam using jet injector with IV midazolam in
performing sedation for doing non-invasive diagnostic pro-
cedures in children aged 1-6 years.
2. Methods
2.1. Study design and setting
This parallel randomized clinical trial was carried out on
traumatized children aged 1-6 years presenting to EDs of
Shahid Sadoughi Hospital and Shahid Rahnemoon Hospitals
in Yazd, central Iran, from April to June 2015, who needed
control and sedation for undergoing a diagnostic procedure.
The research goals and procedures were explained clearly to
the parents and the possible complications of drug admin-
istration (hypoxia, respiratory depression, apnea, coma, hy-
potension, agitation, confusion, and cough) were elucidated
in a crystal-clear fashion. Informed written consent was ob-
tained from the children’s parents. The research proposal
was approved by Committee of Ethics in Research at Shahid
Sadoughi University of Medical Sciences, Yazd, Iran, with
code of ethics no.: IR.SSU.Medicine.REC.1393.30 and regis-
tered in Iranian Registry of Clinical Trials with no.: IRCT no.:
IRCT201510018640N2.
2.2. Participants
Traumatized children aged 1-6 years presenting to EDs of the
mentioned hospitals and in need of sedation for doing non-
invasive diagnostic procedures were enrolled. Un-stable vi-
tal signs, reduced level of consciousness, a positive history
of taking anticonvulsive drugs, allergy to midazolam, lack
of consent for participating in the study, and children with
moderate to severe pain (pains with scores greater than 4 out
of 10 form the researcher’s perspective) were among the ex-
clusion criteria.
2.3. Procedure and data gathering
After history taking and complete medical examination, chil-
dren diagnosed by the medical emergency specialist to be in
need of sedation for performing diagnostic intervention who
met the inclusion criteria were randomly and blindly (with-
out awareness of the researcher and the assessor) assigned
to SC or IV midazolam groups using convenience sampling
method. In doing so, random numbers were selected by a
computer and placed in opaque envelopes, which were num-
bered sequentially. The number in the envelope was placed
in the SC with jet injector group if it was an even number and
in the IV group if it was an odd number. Injection was done
in the brachial area for jet injector patients while IV injec-
tion was performed in the cubital zone after phlebotomy in
the IV group. Phlebotomy was performed by nurses with a
5-year work experience. If phlebotomy failed in the cubital
area of one hand, the other hand was then used for injection.
Midazolam with the initial dose of 0.2 mg/kg was adminis-
tered subcutaneously using jet injector (INJEXT M 30, Carpol
0.3 cc, Needle Free, Made in Germany) in the case group and
given to the IV group with the dose of 0.1 mg/kg by a periph-
eral vein catheter. The assessor was also blind to the site of
injection in both groups not to be aware of the type of injec-
tion. The children underwent cardiac monitoring and pulse
oximetry before the onset of sedation and their level of con-
sciousness was measured by the assessor once per min be-
fore and after sedation (Stage 0: conscious; stage 1: silence;
stage 2: drowsy; stage 3: napping; stage 4: deep sleep). When
the child reached stage 1 of sedation, the intended procedure
was commenced. Successful sedation (achieving stage 1 of
sedation), degree of sedation before and after injection (by
the assessor once per min), and parents’ and the physician’s
satisfaction with the whole process of sedation and diagnos-
tic technique (completely dissatisfied, dissatisfied, indiffer-
ent, satisfied, and completely satisfied) were measured as
primary variables. In addition, the time of regaining full con-
sciousness (level A of AVPU), child control, and the need for
reinjection of drug in the case of failure were assessed as sec-
ondary variables. Child control was defined as the degree of
difficulty in positioning and controlling the child during per-
formance of the procedure for which the physician was asked
by the assessor using a 5-point Likert scale item (very diffi-
cult, difficult, moderate, easy, and very easy). In cases that
the child did not enter stage 1, reinjection was performed
20 minute after the first injection in the case group and 3
minute after the first injection in the control group. If after
one reinjection the required sedation was not achieved, the
procedure was considered as failure and the resident medical
emergency specialist decided on the continuation or discon-
tinuation of the procedure. The child was monitored during
and after completion of the procedure till full consciousness
was reached and the time of full consciousness recovery was
measured.
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Flowchart 1: Enrollment and allocation of patients to the studied groups.
2.4. Statistical Analysis
The sample volume in each group was set at 42 on the ba-
sis of the study by Bennett et al. (12) considering type I error
of 0.05 and type II error of%20, which was increased to 60 to
enhance the validity of the study results. The data were ana-
lyzed by an experienced statistician blind to the groups using
SPSS Ver. 17 (SPSS, Chicago, IL, USA). Descriptive statistics of
mean ± standard deviation and frequency (percentage) were
used to report the results. Also, Chi-square test was used to
analyze nominal data, and independent sample t-test or their
nonparametric equivalents were used to analyze the quanti-
tative data. The level of significance was considered 0.05.
3. Results
3.1. Baseline characteristics of participants
75 children were evaluated, 10 of which were excluded due to
not meeting the inclusion criteria or declining to participate
(flowchart 1). Finally, 60 cases with the mean age of 3.15±1.43
years were randomly assigned into the SC (30 cases) or IV (30
cases) groups (56.7% female). Owing to lack of cooperation,
1 child from the jet injector group and 2 children from the IV
group were excluded from the study. Also, 1 child was omit-
ted from each group due to the parents of the two children
deciding to withdraw from the study (flowchart 1). SC and IV
groups were similar regarding the mean age (2.8 ± 1.2 vs 3.4
± 1.6, respectively; p = 0.165) and sex (56.7% vs 36.7% female,
respectively; p = 0.121).
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Table 1: Comparing the procedural sedation and analgesia (PSA) characteristics of subcutaneous and intravenous midazolam in 1- 6 year old
children
PSA characteristics Subcutaneous n=30 Intravenous n=30 P
Depth of sedation
Fully conscious 5 (16.7) 3 (10.0)
Silent 1 (3.5) 1 (3.3)
Drowsy 0 0 0.900
Napping 1 (3.3) 1 (3.3)
Deep sleep 23 (76.7) 25 (83.3)
Child control
Very difficult 1 (3.3)
Difficult 4 (13.3) 5 (16.7)
Moderate 2 (6.7) 2 (6.7) 0 (0)
Easy 22 (73.3) 23 (76.6)
Very easy 1 (3.3) 0 (0)
Physicians’ satisfaction
Completely dissatisfied 4 (13.3) 4 (13.3)
Dissatisfied 3 (10) 1 (3.3)
Indifferent 1 (3.3) 0 (0) 0.467
Satisfied 8 (26.7) 22 (73.3)
Completely satisfied 14 (46.7) 3 (10.0)
Parents’ satisfaction
Completely dissatisfied 3 (10.0) 4 (13.3)
Dissatisfied 2 (6.7) 7 (23.3)
Indifferent 3 (10.0) 12 (40.0) 0.001
Satisfied 18 (60.0) 6 (20.0)
Completely satisfied 4 (13.3) 1 (3.3)
Successful sedation*
Yes 25 (83.3) 27 (90.0) 0.519
No 5 (16.7) 3 (10.0)
Recovery time (minute)
Mean ± standard deviation 35.8 ± 9.71 24.8 ± 7.60 0.040
Data are presented as number (%). *: Achieving sedation stage 1.
3.2. PSA characteristics of two groups
Table 1 compares the characteristics of PSA between SC and
IV midazolam groups. Two groups were similar regarding
the depth of sedation (p=0.900), control of child (p=0.711),
in-charge physician’s satisfaction (p=0.467), successful seda-
tion and need for rescue dose (p=0.519). IV midazolam group
had a significantly shorter recovery time (about 10 minutes;
p=0.040) and SC midazolam group had significant higher
level of parent satisfaction (p=0.001). None of the possible
midazolam side effects (hypoxia, respiratory depression, ap-
nea, coma, hypotension, agitation, confusion, and cough)
were manifested in any child in this study. Moreover, no der-
mal reaction like arythema, swelling, or inflammation was
observed at the site of injection.
4. Discussion
The findings indicate no significant difference in depth of
sedation, control of child, in-charge physician’s satisfaction,
successful sedation (reaching stage 1 of sedation or higher),
and need for rescue dose between SC and IV midazolam. Par-
ents’ satisfaction was significantly greater with SC adminis-
tration and IV injection had shorter recovery time. The trau-
matized children ought to be controlled and immobilized
during diagnostic procedures such as CT scanning, MRI, ra-
diography, and ultrasonography. There are various medica-
tions with different complications for induction of sedation.
The study by Pecking et al. (2002) conducted in France inves-
tigated the biological power of SC midazolam in volunteers
and the results showed that the biological potency of SC in-
jection of the drug was not significantly different from the IV
injection so that when the IV route was not accessible, the
SC route could be used safely, which is consistent with our
findings (13). Moreover, the study by Greenberg et al. (1995)
explored the effect of administration of different doses of mi-
dazolam with jet injector on 40 children and found that jet
injector administration quickly induced the effect of Mida-
zolam. This is again consistent with our findings (14). The
highly appropriate effect of the drug in the jet injector group
may be attributed to proper distribution of the drug in the
tissue leading to greatly acceptable absorption and the rapid
effect of the drug (12). Generally speaking, although in the
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jet injector method it logically takes longer for the drug to
show its effect compared to the IV method, in the studies
conducted so far the effect of drug is seen faster when using
jet injector compared to the oral route since administration
of the drug using jet injector can induce the intended plasma
level of Midazolam with the same speed as the IM injection of
the drug. Also, when there is oral route resistance in the child
(15) or when there is the need for avoiding phlebotomy ten-
sion in the child, the use of jet injector is a suitable method.
Of course, the time of full recovery in jet injector group was
35.8Âś9.71 minute, which was significantly higher compared
to the IV group. This can be viewed as a weak point of the
method. The study by Bennett et al. (1998) conducted in USA
investigated the effect of SC Midazolam with needle and sy-
ringe compared to the SC injection of this drug using jet in-
jector. The findings of the mentioned clinical trial conducted
on 14 children suggested that the discomfort caused by sub-
cutaneous Midazolam in the jet injector group was less com-
pared to the needle and syringe group though the difference
between the two was not significant. Finally, they concluded
that the peak plasma level was achieved more rapidly with jet
injector probably due to the distribution of the medicine in
the tissue by the jet injector (12). Our findings also suggested
that the parents were significantly more satisfied with jet in-
jector method. In the study by Bennett et al., the rate of dis-
comfort was smaller with jet injector, though the difference
was not significant due to small sample volume (14 samples)
or the study design (12). Overall, parents were more satisfied
with the jet injector method while physicians were less satis-
fied with this route. It appears that the child sustains less pain
and discomfort with the jet injector route causing more satis-
faction among the parents; nonetheless, physicians are more
satisfied with the IV method since the drug exerts its effect
more rapidly leading to faster sedation. However, our results
demonstrated that the physicians in the jet injector group as-
sessed child controlling and positioning of 23 (%76.6) chil-
dren as easy and very easy during the procedure. The same
was true with the IV group indicating another positive factor
in the jet injector method compared to the IV route. Consid-
ering the complications of Midazolam (hypoxia, respiratory
depression, apnea, coma, hypotension, agitation, confusion,
and cough), none of these undesirable side effects were man-
ifested in any child in this study. Moreover, no dermal reac-
tion like erythema, swelling, or inflammation was observed
in the site of injection, a finding which is consistent with the
results obtained by Bennett who reported no specific com-
plication in 14 adult patients who underwent SC Midazolam
injection with jet injector compared to subcutaneous needle
and syringe IV injection (12). Also, the results of the study by
Domino et al. (1998) showed that the SC injection of Midazo-
lam with jet injector was associated with appropriate effect
(16). It seems that SC injection using jet injector as a well-
known old method could be considered as an alternative root
for induction of sedation in pediatric non-invasive diagnos-
tic procedure. Considering the need that is felt for a pain-
less, safe, and rapid-acting method, jet injector as a needle-
less injection system can serve as an effective tool with little
complications to be used for inducing sedation, especially in
stressful situations like ED that demands more tranquility. It
is suggested that future studies investigate other aspects of
these two methods such as comparison of the resulted in-
fection or dermal complications in a longer time interval af-
ter injection. Different jet injectors may be applied for vari-
ous age groups or greater carpols may be used with jet injec-
tors. Additionally, jet injector may be explored for induction
of anesthesia or sedation in painful or invasive procedures.
A combination of the main drug with local anesthetics along
with their merits and demerits is also suggested.
5. Limitation
The children could not be made blind to the study due to the
nature of the use of jet injector. There was no placebo due to
ethical considerations to avoid pain in the children.
6. Conclusion
The findings indicate no significant difference in depth of se-
dation, control of child, in-charge physician satisfaction, suc-
cess rate of sedation (reaching stage 1 of sedation or higher),
and need for rescue dose between SC and IV midazolam. Par-
ents’ satisfaction was significantly greater with SC adminis-
tration and IV injection had shorter recovery time.
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